Major Pharmaceuticals Recalls Thyroid Drug Levothyroxine Nationwide Over Weak Potency

What happened

Major Pharmaceuticals, based out of Indianapolis and Dublin, Ohio, voluntarily recalled multiple lots of levothyroxine sodium tablets on July 13, according to WSB-TV and News4JAX. The FDA classified it as a Class II recall on July 17.

The reason: the pills are "subpotent." That means they contain less active ingredient than they're supposed to, according to the FDA enforcement report cited by all three outlets.

Levothyroxine is a synthetic thyroid hormone. Millions of Americans take it daily for hypothyroidism, a condition where the thyroid doesn't make enough hormone on its own, according to News4JAX. It's one of the most commonly prescribed drugs in the country.

Which lots are affected

The recall covers twelve separate product lines across seven dosage strengths: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 112 mcg, 125 mcg and 150 mcg, according to News4JAX. All were packaged in unit dose blister cartons.

LiveNOW from FOX reported the affected pills were shipped out on January 22, 2025. None of the three sources specified an exact pill count tied to the recall.

Why potency matters here

This isn't a random pill where a slight strength variance is no big deal. Levothyroxine works by directly replacing a hormone your body isn't making enough of. Get the dose wrong, even a little, and patients can drift back into hypothyroid symptoms: fatigue, weight gain, cold sensitivity, brain fog, according to News4JAX.

A subpotent thyroid pill isn't like a subpotent vitamin. Thyroid dosing is dialed in through bloodwork over months, sometimes years. A weaker batch can throw off that balance without anyone immediately realizing why they suddenly feel worse.

The FDA classified this as Class II, not Class I. Class I means a real risk of serious injury or death. Class II, per the FDA's own definition cited by WSB-TV, means the product "may cause temporary or medically reversible adverse health consequences" where serious harm is "remote." This is not being treated as a life-threatening recall.

What the company says

Major Pharmaceuticals told customers the recalled medication is "not likely to cause adverse health effects," according to both LiveNOW from FOX and WSB-TV. That characterization aligns with the FDA's Class II designation.

The company's message to consumers is straightforward: return the recalled product to the place of purchase.

The notification gap

The recall was communicated only through a letter to consignees, not a public press release from the firm, according to News4JAX. That means if you're a patient rather than a pharmacy or distributor, you're not getting a direct heads-up. You have to go check your own pill bottle.

No outlet reported the company issuing a broad public statement beyond the recall letter posted to its own website, which LiveNOW from FOX pointed readers to for lot-specific details.

For a drug this widely used, that's a real gap. If you're one of the millions of Americans on levothyroxine, nobody is mailing you a notice. Your pharmacist might catch it. Your doctor might not think to check unless you ask.

What to actually do

Check the lot number on your prescription bottle against the recalled list, available through the FDA's enforcement report or on Major Pharmaceuticals' recall website. If your dosage strength and lot match, don't just stop taking it cold. Call your pharmacist or physician first, since thyroid hormone withdrawal has its own risks.

If you've been feeling unusually fatigued, foggy, or cold lately and you're on levothyroxine, it's worth asking your pharmacist to check your bottle regardless of whether you remember the lot number offhand.

What's unresolved

None of the three reports specify how many total tablets or bottles are affected nationwide, nor how the subpotency was discovered, whether through routine testing, a patient complaint, or an FDA audit. The FDA's enforcement report, as described by WSB-TV, didn't include a total pill count. Whether Major Pharmaceuticals will issue a broader public statement beyond the private letter to consignees remains an open question as of this week.